
Original ResearchRamucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study
Keywords: سورفانیب; Ramucirumab; Sorafenib; Hepatocellular carcinoma; Patient-focused outcomes; Quality of life; Performance status;